Marcela G Del Carmen1, Laurel W Rice2. 1. Division of Gynecologic Oncology, Vincent Obstetrics and Gynecology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, United States. Electronic address: mdelcarmen@partners.org. 2. Department of Obstetrics and Gynecology, University of Wisconsin Hospital and Clinics, Madison, WI, United States.
Abstract
OBJECTIVE: Women with gynecologic malignancies will be cured or may become long-term survivors. Management of menopausal symptoms is important in addressing their quality of life. We review the benefit and safety of hormone therapy use in these patients. METHODS: MEDLINE was searched for studies on menopause management published in English through December of 2016. RESULTS: Available data suggest that short-term use of hormone therapy in gynecologic cancer patients who do not have an estrogen-dependent malignancy do not adversely impact oncologic outcome and results in improvement of menopausal vasomotor and genitourinary symptoms. Evidence regarding safety of hormone therapy use in women with estrogen-dependent gynecologic malignances is currently lacking. CONCLUSIONS: Candidates for hormone therapy in gynecologic oncology include women with menopausal symptoms diagnosed with low-grade, early-stage endometrial cancer, cervical, vulvar and vaginal cancer, and ovarian cancer.
OBJECTIVE:Women with gynecologic malignancies will be cured or may become long-term survivors. Management of menopausal symptoms is important in addressing their quality of life. We review the benefit and safety of hormone therapy use in these patients. METHODS: MEDLINE was searched for studies on menopause management published in English through December of 2016. RESULTS: Available data suggest that short-term use of hormone therapy in gynecologic cancerpatients who do not have an estrogen-dependent malignancy do not adversely impact oncologic outcome and results in improvement of menopausal vasomotor and genitourinary symptoms. Evidence regarding safety of hormone therapy use in women with estrogen-dependent gynecologic malignances is currently lacking. CONCLUSIONS: Candidates for hormone therapy in gynecologic oncology include women with menopausal symptoms diagnosed with low-grade, early-stage endometrial cancer, cervical, vulvar and vaginal cancer, and ovarian cancer.
Authors: Lisa A Rubinsak; Mindy S Christianson; Aletha Akers; Jeanne Carter; Andrew M Kaunitz; Sarah M Temkin Journal: Support Care Cancer Date: 2018-07-26 Impact factor: 3.603
Authors: Carolyn S Harris; Kord M Kober; Bruce Cooper; Yvette P Conley; Anand A Dhruva; Marilyn J Hammer; Steven Paul; Jon D Levine; Christine A Miaskowski Journal: Support Care Cancer Date: 2022-05-11 Impact factor: 3.603
Authors: Connor C Wang; Dandi S Huang; Anisa M Carlson; Zhanhai Li; Ahmed Al-Niaimi; Makeba Williams Journal: Menopause Date: 2022-08-01 Impact factor: 3.310